



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Oxypurinol-¹³C,¹⁵N₂

Cat. No.:	HY-19657S
Molecular Formula:	C ₄ ¹³ CH ₄ N ₂ ¹⁵ N ₂ O ₂
Molecular Weight:	155.09
Target:	Drug Metabolite; Xanthine Oxidase; Endogenous Metabolite; Isotope-Labeled Compounds
Pathway:	Metabolic Enzyme/Protease; Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Oxypurinol- ¹³ C, ¹⁵ N ₂ is ¹⁵ N and ¹³ C labeled Oxypurinol (HY-19657). Oxypurinol (Oxipurinol), the major active metabolite of Allopurinol, is an inhibitor of xanthine oxidase. Oxypurinol can be used to regulate blood urate levels and treat gout ^[1] .
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1]. Allopurinol is rapidly metabolized (half-life approximately 1 h) to its active metabolite oxypurinol. Oxypurinol is an inhibitor of xanthine oxidoreductase and has a considerably longer elimination half-life (approximately 23 h)^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Stocker SL, et al. The pharmacokinetics of oxypurinol in people with gout. Br J Clin Pharmacol. 2012 Sep;74(3):477-89.
- [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA